Neurogene Inc.
NGNE
$16.80
-$0.98-5.51%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 925.00K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 925.00K | -- | -- | -- |
| Cost of Revenue | 16.29M | 15.74M | 13.44M | 12.18M | 11.61M |
| Gross Profit | -16.29M | -14.82M | -13.44M | -12.18M | -11.61M |
| SG&A Expenses | 5.90M | 5.32M | 5.24M | 2.55M | 3.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.18M | 21.06M | 18.68M | 14.73M | 15.22M |
| Operating Income | -22.18M | -20.13M | -18.68M | -14.73M | -15.22M |
| Income Before Tax | -20.22M | -18.49M | -16.92M | 2.38M | -14.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.22M | -18.49M | -16.92M | 2.38M | -14.58M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.22M | -18.49M | -16.92M | 2.38M | -14.58M |
| EBIT | -22.18M | -20.13M | -18.68M | -14.73M | -15.22M |
| EBITDA | -21.37M | -19.32M | -17.85M | -13.91M | -14.39M |
| EPS Basic | -1.19 | -1.09 | -1.00 | 47.25 | -32.67 |
| Normalized Basic EPS | -0.75 | -0.68 | -0.62 | -7.88 | -20.42 |
| EPS Diluted | -1.19 | -1.09 | -1.00 | 47.24 | -32.67 |
| Normalized Diluted EPS | -0.75 | -0.68 | -0.62 | -7.88 | -20.42 |
| Average Basic Shares Outstanding | 16.95M | 16.94M | 16.90M | 1.11M | 446.30K |
| Average Diluted Shares Outstanding | 16.95M | 16.94M | 16.90M | 1.11M | 446.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
